An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the clinical and endoscopic remission of disease, reduce the incidence of complications such as dysplasia and colorectal carcinoma and improve quality of life. Although a curative medical treatment for UC has not yet...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/9/2302 |
| _version_ | 1797504297644064768 |
|---|---|
| author | Francesca Ferretti Rosanna Cannatelli Maria Camilla Monico Giovanni Maconi Sandro Ardizzone |
| author_facet | Francesca Ferretti Rosanna Cannatelli Maria Camilla Monico Giovanni Maconi Sandro Ardizzone |
| author_sort | Francesca Ferretti |
| collection | DOAJ |
| description | The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the clinical and endoscopic remission of disease, reduce the incidence of complications such as dysplasia and colorectal carcinoma and improve quality of life. Although a curative medical treatment for UC has not yet been found, new therapeutic strategies addressing specific pathogenetic mechanisms of disease are emerging. Notwithstanding these novel therapies, non-biological conventional drugs remain a mainstay of treatment. The aim of this review is to summarize current therapeutic strategies used as treatment for ulcerative colitis and to briefly focus on emerging therapeutic strategies, including novel biologic therapies and small molecules. To date, multiple therapeutic approaches can be adopted in UC and the range of available compounds is constantly increasing. In this era, the realization of well-designed comparative clinical trials, as well as the definition of specific therapeutic models, would be strongly suggested in order to achieve personalized management for UC patients. |
| first_indexed | 2024-03-10T04:02:38Z |
| format | Article |
| id | doaj.art-a3aacdbba43e4dbcbf648c1ddf0c4ec6 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T04:02:38Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-a3aacdbba43e4dbcbf648c1ddf0c4ec62023-11-23T08:30:23ZengMDPI AGJournal of Clinical Medicine2077-03832022-04-01119230210.3390/jcm11092302An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative ColitisFrancesca Ferretti0Rosanna Cannatelli1Maria Camilla Monico2Giovanni Maconi3Sandro Ardizzone4Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, “Luigi Sacco” University Hospital, 20157 Milan, ItalyGastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, “Luigi Sacco” University Hospital, 20157 Milan, ItalyGastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, “Luigi Sacco” University Hospital, 20157 Milan, ItalyGastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, “Luigi Sacco” University Hospital, 20157 Milan, ItalyGastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, “Luigi Sacco” University Hospital, 20157 Milan, ItalyThe main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the clinical and endoscopic remission of disease, reduce the incidence of complications such as dysplasia and colorectal carcinoma and improve quality of life. Although a curative medical treatment for UC has not yet been found, new therapeutic strategies addressing specific pathogenetic mechanisms of disease are emerging. Notwithstanding these novel therapies, non-biological conventional drugs remain a mainstay of treatment. The aim of this review is to summarize current therapeutic strategies used as treatment for ulcerative colitis and to briefly focus on emerging therapeutic strategies, including novel biologic therapies and small molecules. To date, multiple therapeutic approaches can be adopted in UC and the range of available compounds is constantly increasing. In this era, the realization of well-designed comparative clinical trials, as well as the definition of specific therapeutic models, would be strongly suggested in order to achieve personalized management for UC patients.https://www.mdpi.com/2077-0383/11/9/23025-aminosalicylic acidazathioprinebiologic therapycorticosteroidsinflammatory bowel diseasesmall molecule |
| spellingShingle | Francesca Ferretti Rosanna Cannatelli Maria Camilla Monico Giovanni Maconi Sandro Ardizzone An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis Journal of Clinical Medicine 5-aminosalicylic acid azathioprine biologic therapy corticosteroids inflammatory bowel disease small molecule |
| title | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis |
| title_full | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis |
| title_fullStr | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis |
| title_full_unstemmed | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis |
| title_short | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis |
| title_sort | update on current pharmacotherapeutic options for the treatment of ulcerative colitis |
| topic | 5-aminosalicylic acid azathioprine biologic therapy corticosteroids inflammatory bowel disease small molecule |
| url | https://www.mdpi.com/2077-0383/11/9/2302 |
| work_keys_str_mv | AT francescaferretti anupdateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT rosannacannatelli anupdateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT mariacamillamonico anupdateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT giovannimaconi anupdateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT sandroardizzone anupdateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT francescaferretti updateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT rosannacannatelli updateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT mariacamillamonico updateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT giovannimaconi updateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis AT sandroardizzone updateoncurrentpharmacotherapeuticoptionsforthetreatmentofulcerativecolitis |